Xbrane Biopharma AB (ST:XBRANE) — Market Cap & Net Worth
Market Cap & Net Worth: Xbrane Biopharma AB (XBRANE)
Xbrane Biopharma AB (ST:XBRANE) has a market capitalization of $24.39 Million (Skr226.66 Million) as of May 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #24406 globally and #480 in its home market, demonstrating a 11.11% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Xbrane Biopharma AB's stock price Skr11.00 by its total outstanding shares 20605348 (20.61 Million). Analyse XBRANE operating cash flow to see how efficiently the company converts income to cash.
Xbrane Biopharma AB Market Cap History: 2016 to 2026
Xbrane Biopharma AB's market capitalization history from 2016 to 2026. Data shows change from $85.14 Million to $24.39 Million (-10.34% CAGR).
Xbrane Biopharma AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Xbrane Biopharma AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.15x
Xbrane Biopharma AB's market cap is 0.15 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.18x
Xbrane Biopharma AB's market cap is 0.18 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $85.14 Million | $2.49 Million | -$33.29 Million | 34.19x | N/A |
| 2017 | $138.22 Million | $20.77 Million | -$44.94 Million | 6.65x | N/A |
| 2018 | $96.49 Million | $112.95 Million | -$13.24 Million | 0.85x | N/A |
| 2019 | $76.72 Million | $600.00K | -$167.47 Million | 127.87x | N/A |
| 2020 | $165.87 Million | $6.82 Million | -$226.79 Million | 24.32x | N/A |
| 2021 | $232.39 Million | $11.53 Million | -$191.01 Million | 20.15x | N/A |
| 2022 | $182.05 Million | $57.62 Million | -$172.23 Million | 3.16x | N/A |
| 2023 | $22.17 Million | $238.73 Million | -$388.17 Million | 0.09x | N/A |
| 2024 | $356.57K | $198.70 Million | -$266.22 Million | 0.00x | N/A |
| 2025 | $22.62 Million | $152.35 Million | $127.24 Million | 0.15x | 0.18x |
Competitor Companies of XBRANE by Market Capitalization
Companies near Xbrane Biopharma AB in the global market cap rankings as of May 4, 2026.
Key companies related to Xbrane Biopharma AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Xbrane Biopharma AB Historical Marketcap From 2016 to 2026
Between 2016 and today, Xbrane Biopharma AB's market cap moved from $85.14 Million to $ 24.39 Million, with a yearly change of -10.34%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr24.39 Million | +7.84% |
| 2025 | Skr22.62 Million | +6243.28% |
| 2024 | Skr356.57K | -98.39% |
| 2023 | Skr22.17 Million | -87.82% |
| 2022 | Skr182.05 Million | -21.66% |
| 2021 | Skr232.39 Million | +40.11% |
| 2020 | Skr165.87 Million | +116.18% |
| 2019 | Skr76.72 Million | -20.49% |
| 2018 | Skr96.49 Million | -30.19% |
| 2017 | Skr138.22 Million | +62.35% |
| 2016 | Skr85.14 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Xbrane Biopharma AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $24.39 Million USD |
| MoneyControl | $24.39 Million USD |
| MarketWatch | $24.39 Million USD |
| marketcap.company | $24.39 Million USD |
| Reuters | $24.39 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Xbrane Biopharma AB
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularizati… Read more